Tech Company Financing Transactions

Oyster Point Pharmaceuticals Funding Round

On 2/27/2019, Oyster Point Pharmaceuticals raised $93 million in Series B funding from Flying L Partners, Invus and New Enterprise Associates.

Transaction Overview

Company Name
Oyster Point Pharmaceuticals
Announced On
2/27/2019
Transaction Type
Venture Equity
Amount
$93,000,000
Round
Series B
Investors

Flying L Partners (Lead Investor) (William Link)

Invus (Lead Investor) (Benjamin Tsai)

New Enterprise Associates (Ali Behbahani)

Versant Ventures (Clare Ozawa)

Vida Ventures

Proceeds Purpose
Oyster Point will use the proceeds to support the development of its product portfolio for Dry Eye Disease, explore new treatment areas, and add key talent.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
202 Carnegie Center 109
Princeton, NJ 08540
USA
Phone
(609) 382-9032
Website
www.oysterpointrx.com
Email Address
[email protected]
Overview
Oyster Point Pharma (Nasdaq: OYST) is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapies to treat ocular surface disease.
Profile
Oyster Point Pharmaceuticals LinkedIn Company Profile
Social Media
Oyster Point Pharmaceuticals Company Twitter Account
Company News
Oyster Point Pharmaceuticals News
Facebook
Oyster Point Pharmaceuticals on Facebook
YouTube
Oyster Point Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Jeffrey Nau
  Jeffrey Nau LinkedIn Profile  Jeffrey Nau Twitter Account  Jeffrey Nau News  Jeffrey Nau on Facebook
Chief Financial Officer
Daniel Lochner
  Daniel Lochner LinkedIn Profile  Daniel Lochner Twitter Account  Daniel Lochner News  Daniel Lochner on Facebook
VP - Bus. Development
John Snisarenko
  John Snisarenko LinkedIn Profile  John Snisarenko Twitter Account  John Snisarenko News  John Snisarenko on Facebook
VP - General Counsel
Jill Andersen
  Jill Andersen LinkedIn Profile  Jill Andersen Twitter Account  Jill Andersen News  Jill Andersen on Facebook
VP - Marketing
Dawn Koffler
  Dawn Koffler LinkedIn Profile  Dawn Koffler Twitter Account  Dawn Koffler News  Dawn Koffler on Facebook
VP - Regulatory Affairs
Loni Da Silva
  Loni Da Silva LinkedIn Profile  Loni Da Silva Twitter Account  Loni Da Silva News  Loni Da Silva on Facebook

 

 

Browse more venture capital transactions:

Prev: 2/27/2019: Hyliion venture capital transaction
Next: 2/27/2019: Medstack venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to record tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.